Objective To explore the efficacy of liraglutide sequential insulin pump in the treatment of newly-diagnosed obesity with type 2 diabetes mellitus (T2DM) and its influence on glucolipid metabolism, islet function and body weight-related indicators.Methods 104 T2DM patients with obesity ［body mass index (BMI) ≥28 kg/m2］admitted to department of endocrinology of our hospital from April 2018 to April 2022 were selected and had fasting plasma glucose (FPG)≥11.1 mmol/L and/or glycated hemoglobin (HbA1c) ≥9%. All patients were divided into conventional group (odd number, n=52) and GLP-1 group (even number, n=52) according to the odd-even number method. Both groups were treated with intensive insulin pump (CSII) for 2 weeks, and the blood glucose control was up to standard. After the pump was withdrawn, the conventional group was given metformin while the GLP-1 group was given liraglutide. The two groups were treated for 10 weeks. The body weight-related indicators (BMI, waist circumference), glucose metabolism ［FPG, 2h postprandial blood glucose (2hPG) and HbA1c］, lipid metabolism ［apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB), total cholesterol (TC) and triglyceride (TG)］, insulin resistance ［homeostasis model assessment of islet β cell index (HOMA-β), homeostasis model assessment of insulin resistance (HOMA-IR)］ were compared between the two groups before and after treatment, and the adverse drug reactions were counted. Results After treatment, the BMI, waist circumference, FPG, 2hPG, HbA1c, ApoB, TC, TG and HOMA-IR were significantly decreased in the two groups (P＜0.05), and the above indicators in GLP-1 group were significantly lower than those in conventional group (P＜0.05). The ApoA1 and HOMA-β in the two groups were significantly risen (P＜0.05). There was no significant difference in the total adverse drug reaction rate between GLP-1 group (5.77%) and conventional group (3.85%) (P＞0.05).Conclusion Liraglutide sequential CSII can significantly improve the body fat, glucolipid metabolism and insulin resistance in patients with obesity and T2DM, and it has few adverse reactions and is safe and effective